Stakeholders across the clinical trials and digital health industry will be gathering next month in Orlando at the Summit for Clinical OPS Executives (SCOPE) 2025. With decentralized clinical trials increasingly gathering attention in the pharmaceutical industry, accompanied by rapid market growth, advancements in this area will be one of the major topics of discussion during the event.
Medable, a company developing digital clinical trial technology, will be taking part in SCOPE’s 16th edition to showcase some of the latest developments in decentralized clinical trial technology and beyond. Medable’s AI platform, designed to enhance speed, scale, and patient access in clinical research, has been deployed in nearly 400 trials in 70 countries and 120 languages, serving over a million patients globally.
What milestones has Medable hit since the previous SCOPE event in 2024?
Since 2024’s SCOPE, Medable has made huge strides in product, internal process, client workflows, and more. We launched both Medable Studio and Medable AI, enabling greater control over electronic Clinical Outcome Assessment (eCOA) build and launch while providing 35x faster build times. We also achieved some outstanding study delivery milestones, including 100% study go-live, 100% on-time study delivery and 98% on-time device delivery for our customers.
What will be the highlights of SCOPE for your team this year?
This year, Medable will be highlighting its newest product innovations, including Medable Studio, an all-in-one application for configuring, translating, validating, and launching eCOA+ (eCOA, electronic consent, televisit, and sensors) into clinical trials. This no-code suite simplifies the complex eCOA launch process, giving biopharmaceutical companies greater control and transparency for faster study go-live and earlier patient enrollment.
Also, we will be discussing how Medable AI – our generative AI capabilities – is integrated into Medable Studio to help accelerate research. As part of a broader AI strategy, Medable AI will initially deliver many new capabilities, such as automatically converting existing outcomes assessments into fully digital eCOAs in seconds.
I’m personally thrilled to showcase how Studio has fulfilled its promise of enhancing control and transparency in my session, on February 5. Together with Christina Fawcet, Director of Digital Health Delivery at GSK, we will dive deeper into the need for greater control during study launch and explore the benefits it brings to study success.
Dr. Pamela Tenaerts and Ken Getz will also be discussing new data from the Tufts Center for the Study of Drug Development (CSDD) Partnership for Advancing Clinical Trials (PACT) Consortium that reveals higher participation across multiple underrepresented demographic groups in trials using decentralized elements. The research shows that Asian participation increased by six percentage points; American Indian and Alaska Native participation quadrupled; and female participation rose from 49.0% to 55.7%.
What do you expect to achieve from the event in this year’s edition?
As always, we look to deepen our existing relationships and partnerships at SCOPE. However, this year we are also using it as a “re-introduction” to the industry. The Medable of 2025 isn’t the Medable you knew from a few years ago. We hope people stop by to learn about all the exciting advancements we’ve made in the past year and what is yet to come.
How do you see the coming year panning out for Medable?
We are excited! Last year’s product infrastructure updates put us in a fantastic position to continue evolving quickly and releasing new features to the Medable platform – everything from more AI integration to site experience enhancements. We have a few things cooking this year and are excited to get them into the hands of trial sponsors, site teams, and contract research organizations (CROs) and to continue to facilitate the increased control that this industry needs to meet its objectives.
